• Jun Yeun Cho, Ok-Jun Lee, Jihyun Kwon, Dohun Kim, and Yoon Mi Shin.
• Department of Internal Medicine, Chungbuk National University Hospital, Chungbuk National University College of Medicine, Cheongju, Korea.
• Medicine (Baltimore). 2022 Jan 28; 101 (4): e28701e28701.

RationaleNilotinib is a second line tyrosine kinase inhibitor to treat patients with chronic myeloid leukemia after imatinib resistance or intolerance. Drug related pulmonary complication is known to be rare. We discuss a case of nilotinib-induced interstitial lung disease presenting with nonspecific interstitial pneumonia on the unilateral lung.Patient ConcernsA 46-year-old man with chronic-phase chronic myeloid leukemia presented with cough and weight loss for 2 months. He had been treated with nilotinib for 52 months.DiagnosisComputed tomography scan showed right lung dominant consolidations, ground glass opacities and traction bronchiectasis. Bronchoalveolar lavage fluid analysis revealed no evidence of infection or malignancy. Surgical lung biopsy specimen was consistent with fibrosing nonspecific interstitial pneumonia. The patient was diagnosed with nilotinib induced interstitial lung disease.InterventionsCorticosteroid treatment was initiated with prednisolone (50 mg daily) and slowly tapered down for 2 months.OutcomesCough improved after the course of corticosteroid treatment. However, fibrotic lung lesions persisted. Reinitiation of nilotinib resulted in the worsening of lung lesions.LessonsWe report a case of irreversible interstitial lung disease that caused by nilotinib. Clinicians should have suspicion of this potential pulmonary complication in patients with respiratory symptoms and abnormal radiologic findings during nilotinib treatment, albeit rarely.Copyright © 2022 the Author(s). Published by Wolters Kluwer Health, Inc.

35 keywords...

hide…